Onivyde (Irinotecan Liposome)
- Medicine Name: Onivyde
- API: Irinotecan Liposome
- Dosage Form & Strength: Injection: 43 mg/10 mL single-dose vial
- Manufactured By: Merrimack Pharmaceuticals, Inc.
Onivyde (irinotecan liposome) is a topoisomerase inhibitor used, together with medicines fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression post-gemcitabine-based therapy.
Limitation of Use: This medicinal product is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas.
Recommended Dosage: The recommended dosage of Onivyde injection is 70 mg/m2 administered (prior to leucovorin and fluorouracil) by intravenous (IV) infusion over 90 minutes every 14 days (2 weeks). The recommended initial dosage in patients known to be homozygous for the UGT1A1*28 allele is 50 mg/m2 administered by intravenous (IV) infusion over 90 minutes. The dosage can be increased to 70 mg/m2 as tolerated in subsequent cycles.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.